Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial
2011 ◽
Vol 99
(3)
◽
pp. 356-361
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 5588-5588
2004 ◽
Vol 22
(14_suppl)
◽
pp. 5588-5588
◽
2020 ◽
Vol 130
(1)
◽
pp. 32-42.e4
2010 ◽
Vol 28
(15_suppl)
◽
pp. 5520-5520